GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Gross Margin %

Kyorin Pharmaceutical Co (TSE:4569) Gross Margin % : 45.37% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Kyorin Pharmaceutical Co's Gross Profit for the three months ended in Dec. 2023 was 円14,669 Mil. Kyorin Pharmaceutical Co's Revenue for the three months ended in Dec. 2023 was 円32,330 Mil. Therefore, Kyorin Pharmaceutical Co's Gross Margin % for the quarter that ended in Dec. 2023 was 45.37%.

Warning Sign:

Kyorin Pharmaceutical Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -3.9%.


The historical rank and industry rank for Kyorin Pharmaceutical Co's Gross Margin % or its related term are showing as below:

TSE:4569' s Gross Margin % Range Over the Past 10 Years
Min: 42.92   Med: 53.76   Max: 61.36
Current: 42.92


During the past 13 years, the highest Gross Margin % of Kyorin Pharmaceutical Co was 61.36%. The lowest was 42.92%. And the median was 53.76%.

TSE:4569's Gross Margin % is ranked worse than
58.11% of 986 companies
in the Drug Manufacturers industry
Industry Median: 46.375 vs TSE:4569: 42.92

Kyorin Pharmaceutical Co had a gross margin of 45.37% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Kyorin Pharmaceutical Co was -3.90% per year.


Kyorin Pharmaceutical Co Gross Margin % Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Gross Margin % Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.53 51.86 50.17 46.85 44.29

Kyorin Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.85 40.27 43.91 42.14 45.37

Competitive Comparison of Kyorin Pharmaceutical Co's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Gross Margin % falls into.



Kyorin Pharmaceutical Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Kyorin Pharmaceutical Co's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )=Gross Profit (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=50167 / 113270
=(Revenue - Cost of Goods Sold) / Revenue
=(113270 - 63103) / 113270
=44.29 %

Kyorin Pharmaceutical Co's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=14669 / 32330
=(Revenue - Cost of Goods Sold) / Revenue
=(32330 - 17661) / 32330
=45.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Kyorin Pharmaceutical Co  (TSE:4569) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Kyorin Pharmaceutical Co had a gross margin of 45.37% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Kyorin Pharmaceutical Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines